Jordi Xiol is a Principal at Ysios Capital. He currently serves on the board of Northsea Therapeutics, and as an observer on the board of Adcendo, Cytoki and Splice Bio.
Jordi has more than 10 years’ experience in biomedical research. He completed a PhD at the European Molecular Biology Laboratory (EMBL), where he studied fundamental aspects of non-coding RNA biology. As a post-doctoral fellow at Harvard University, Jordi worked on the development of novel therapeutic strategies for colorectal cancer by studying signalling pathways in cancer stem cells. Jordi has published lead author papers in top-tier peer-reviewed journals such as Cell, Molecular Cell and Cell Stem Cell. Prior to joning Ysios Jordi worked at Vida Ventures, where he focused on opportunities in oncology, gene therapy and ophthalmology. Jordi holds a Bachelor´s degree in Biochemistry from the University of Barcelona.